

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Travoprost Ophthalmic Solution (DIN 02413167) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 15, 2021**. The following grouping was removed from the Critical Supply Product List **March 15, 2021**.

TRAVOPROST

0.004 % OPHTHALMIC SOLUTION

00002415739	APO-TRAVOPROST Z	APX	\$ 4.0264
00002413167	SANDOZ TRAVOPROST	SDZ	\$ 4.0264
00002318008	TRAVATAN Z	NOV	\$ 11.6960

Alberta Blue Cross has been advised by Viatrix Canada (Mylan Pharmaceuticals ULC) that the shortage for Mylan-Verapamil SR 120 mg Tablet (DIN 02210347) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 19, 2021**. The following grouping was removed from the Critical Supply Product List **March 16, 2021**.

VERAPAMIL HCL

120 MG SUSTAINED-RELEASE TABLET

00002246893	APO-VERAP SR	APX	\$ 0.5078
00002210347	MYLAN-VERAPAMILSR	MYP	\$ 0.5078
00001907123	ISOPTIN SR	BGP	\$ 1.5178

Alberta Blue Cross has been advised by Omega Laboratories Limited that the shortage for Octreotide Acetate Omega 100 mcg/ml Injection (DIN 02248640) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 28, 2021**. The following grouping was removed from the Critical Supply Product List **March 29, 2021**.

OCTREOTIDE ACETATE

100 MCG / ML INJECTION

00002248640	OCTREOTIDE ACETATE OMEGA	OMG	\$ 7.5660
00000839205	SANDOSTATIN	NOV	\$ 9.7135

continued next page

continued from previous page

Temporary benefit added to the ADBL

Due to the unavailability of Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc. and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Aldactone 100 mg Tablet (DIN 00285455) will be considered as a temporary benefit for the ADBL. The following grouping was added to the Critical Supply Product List **March 17, 2021**.

As of **March 17, 2021**, all claims for Aldactone 100 mg Tablet (DIN 00285455) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at www.ab.bluecross.ca/providers/pharmacy-home.php

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the ADBL to remain as a benefit.

Temporary benefit added to the Alberta Human Services Drug Benefit Supplement (HSBDS)

Due to the unavailability Ene-Med Rectal Enema (NPN 02231170) manufactured by H.J. Sutton/Quality Home Products and Fleet Rectal Enema (NPN 00009911) manufactured by C.B. Fleet Company Inc, Lax-A Nema Rectal Enema (NPN 02096900) will be considered as a temporary benefit for the *Alberta HSDBS*. The following grouping was added to the Critical Supply Product List **March 22, 2021**.

As of **March 22, 2021**, all claims for Lax-A Nema Rectal Enema (NPN 02096900) will be adjudicated to the price published in the most recent ABCDPL until further notice. The ABCDPL is available online at www.ab.bluecross.ca/providers/pharmacy-home.php

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the HSDBS in order to remain as a benefit.

Due to the unavailability Sandoz Dimenhydrinate 50 mg Rectal Suppository (DIN 00392553) and Sandoz Dimenhydrinate 100 mg Rectal Suppository (DIN 00392545) manufactured by Sandoz Canada Inc, Gravol Adult 100 mg Rectal Suppository (DIN 00013609) will be considered as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSBDS)*. The following grouping was added to the Critical Supply Product List **March 25, 2021**.

As of **March 25, 2021**, all claims for Gravol Adult 100 mg Rectal Suppository (DIN 00013609) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at www.ab.bluecross.ca/providers/pharmacy-home.php

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the HSDBS to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

